NASDAQ:AGIO
Agios Pharmaceuticals - AGIO Stock Forecast, Price & News
Adding Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals MarketRank™ Forecast
Moderate Buy
12.68% of Float Sold Short
$577,000 Sold Last Quarter
From ($6.53) to ($6.50) Per Share
Agios Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
According to analysts' consensus price target of $53.33, Agios Pharmaceuticals has a forecasted upside of 84.0% from its current price of $28.99.
Agios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.
12.68% of the float of Agios Pharmaceuticals has been sold short.
Agios Pharmaceuticals has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.
Short interest in Agios Pharmaceuticals has recently decreased by 1.18%, indicating that investor sentiment is improving.
Agios Pharmaceuticals does not currently pay a dividend.
Agios Pharmaceuticals does not have a long track record of dividend growth.
Agios Pharmaceuticals has received a 73.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
The Environmental Impact score for Agios Pharmaceuticals is -0.87.
Agios Pharmaceuticals has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
MarketBeat has tracked 2 news articles for Agios Pharmaceuticals this week, compared to 2 articles on an average week.
4 people have searched for AGIO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
Only 1 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $577,000.00 in company stock.
Only 4.48% of the stock of Agios Pharmaceuticals is held by insiders.
Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.53) to ($6.50) per share.
The P/E ratio of Agios Pharmaceuticals is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Agios Pharmaceuticals has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
About Agios Pharmaceuticals (NASDAQ:AGIO) Stock
Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Receive AGIO Stock News and Ratings via Email
Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
AGIO Stock News Headlines
January 30, 2023 | marketwatch.com
Cholangiocarcinoma Pipeline Market 2023 : Trends, Industry Size, Share, Emerging Trends, Top Leading Players and Forecast 2028
Insider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Sells 20,000 Shares of Stock
January 30, 2023 | Investing Trends (Ad)
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down to $29.77
Shareholders in Agios Pharmaceuticals (NASDAQ:AGIO) are in the red if they invested five years ago
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company's Vision to Transform Patient Outcomes in Rare Diseases
January 7, 2023 | forbes.com
Agios Pharmaceuticals
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
December 22, 2022 | uk.finance.yahoo.com
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
December 12, 2022 | seekingalpha.com
Agios rare blood disorder drug Pyrukynd sustains benefits in patients in long term data
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition
December 6, 2022 | finance.yahoo.com
Agios Appoints Tsveta Milanova as Chief Commercial Officer
Agios to Participate in December Investor Conference
Alexion's new U.S. head is looking for 'the next generation of medicines to unpack'
Agios Pharmaceuticals upgraded to neutral at Goldman Sachs on Pyrukynd outlook
Agios Pharmaceuticals's Return On Capital Employed Overview
The Petri Dish: Moderna touts new booster; MGH spins out diagnostics startup
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 34%?
Agios Pharmaceuticals, Inc. (AGIO) Q3 2022 Earnings Call Transcript
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
AGIO Company Calendar
www.agios.com
Brian M. Goff
Chief Executive Officer & Director
Cecilia Jones
Clive Patience
Executive Vice President-Technical Operations
Sarah Gheuens
Chief Medical Officer, Head-Research & Development
Tsveta Milanova
Pliant Therapeutics
NASDAQ:PLRX
Arcus Biosciences
NYSE:RCUS
Rocket Pharmaceuticals
NASDAQ:RCKT
Arvinas
NASDAQ:ARVN
Chinook Therapeutics
NASDAQ:KDNY
David P Schenkein
Total: $577,000.00 ($28.85/share)
Hennion & Walsh Asset Management Inc.
Bought 20,410 shares on 12/8/2022
AGIO Stock - Frequently Asked Questions
Should I buy or sell Agios Pharmaceuticals stock right now?
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings or view top-rated stocks.
What is Agios Pharmaceuticals' stock price forecast for 2023?
6 equities research analysts have issued 1 year target prices for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $32.00 to $96.00. On average, they expect the company's stock price to reach $53.33 in the next year. This suggests a possible upside of 85.4% from the stock's current price.
View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts.
How have AGIO shares performed in 2023?
Agios Pharmaceuticals' stock was trading at $28.08 on January 1st, 2023. Since then, AGIO stock has increased by 2.5% and is now trading at $28.77.
When is Agios Pharmaceuticals' next earnings date?
View our AGIO earnings forecast.
How were Agios Pharmaceuticals' earnings last quarter?
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.75) by $0.26. The biopharmaceutical company earned $3.52 million during the quarter, compared to analyst estimates of $5.24 million. During the same quarter in the previous year, the company earned ($1.48) EPS.
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?
11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Agios Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).
What is Agios Pharmaceuticals' stock symbol?
Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."
Who are Agios Pharmaceuticals' major shareholders?
Agios Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.20%), Hennion & Walsh Asset Management Inc. (0.04%), Inspire Investing LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles, David P Schenkein and Theodore James Jr Washburn.
How do I buy shares of Agios Pharmaceuticals?
Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
What is Agios Pharmaceuticals' stock price today?
One share of AGIO stock can currently be purchased for approximately $28.77.
How much money does Agios Pharmaceuticals make?
Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.58 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $1.60 billion in net income (profit) each year or ($6.65) on an earnings per share basis.
How many employees does Agios Pharmaceuticals have?
The company employs 390 workers across the globe.
How can I contact Agios Pharmaceuticals?
Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.
This page (NASDAQ:AGIO) was last updated on 1/30/2023 by MarketBeat.com Staff